US Patent

US11951153 — Topical cyclosporine-containing formulations and uses thereof

Method of Use · Assigned to Sun Pharmaceutical Industries Ltd · Expires 2037-02-28 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects topical ophthalmic formulations containing cyclosporine and methods for making and using them to treat or prevent ocular diseases or conditions.

USPTO Abstract

Provided herein are formulations for topical ophthalmic formulations containing 0.087-0.093 wt % of cyclosporine, and methods of making and using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also included herein are methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1483 — Sandimmune

Patent Metadata

Patent number
US11951153
Jurisdiction
US
Classification
Method of Use
Expires
2037-02-28
Drug substance claim
No
Drug product claim
No
Assignee
Sun Pharmaceutical Industries Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.